Study: Heart attack patients might not benefit from anemia drugs

05/10/2011 | Bloomberg

A study in the Journal of the American Medical Association found no difference in the extent of damage caused by a heart attack between patients given an erythropoiesis-stimulating agent and placebo after angioplasty. Researchers also found that patients age 70 and older who received an erythropoiesis drug had greater heart damage. The agent, typically used to treat anemia, is marketed as Aranesp and Epogen by Amgen and Procrit by Johnson & Johnson.

View Full Article in:

Bloomberg

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice-President of Technology and Regulatory Affairs
AdvaMed
Washington DC, DC
Sr Product Manager Global Marketing (US/DA/00/0085/SL) - 14000009V3
Abbott
Chicago, IL
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Vice President, Information Technology
HealthPartners
MN